The advancements in immunotherapy have revolutionized cancer treatment, offering a new line of defense against this deadly disease. A key player in this field is the T lymphocyte cell, which has shown to be a pivotal player in lung cancer treatment.
Immunotherapy, along with chemotherapy, targeted delivery, radiation, and surgery, has become one of the most common cancer treatments. The aim of immunology is to use the body's immune system to combat tumors and develop a robust antitumor response. In recent years, checkpoint inhibitors and chimeric antigen receptor-modified T cells have made substantial advancements in immunotherapy.
By boosting cell type-specific delivery and immunological responses, nanocarriers like liposomes have the ability to enhance greater responses. The efficacy of anti-tumor therapeutics is being significantly improved as they can assist in resolving a number of issues that arise from a variety of immunotherapies.
These advancements were highlighted in the G20 Global Pharma Summit Series-Canada, where leading researchers and pharmaceutical companies came together to discuss the future of cancer treatment.